Ipilimumab was firstly approved for advanced melanoma in 2011 (Ma et al., 2016), which symbolizes the remarkable clinical success of anti-CTLA-4 and thus elicits further investigations into PD-1/PD-L1 pathway. Here, PDCD1 is linked to melanoma.